When the scale stalls, the first instinct is usually to ask for a higher dose. Sometimes that's the right call. But dose and weight loss don't move in lockstep, and a plateau often has less to do with your medication than it seems.
Does a higher dose mean more weight loss?
Up to a point. Trials do show that higher doses lead to more weight loss on average, but the gains shrink toward the top of the range. In the SURMOUNT-1 trial, average weight loss at 72 weeks was 15.0% on 5 mg of tirzepatide, 19.5% on 10 mg, and 20.9% on 15 mg (DOI (external link)). Most of the extra benefit came between 5 and 10 mg.
Semaglutide now has a similar data point. In the STEP UP trial, adults with obesity who took semaglutide 7.2 mg for 72 weeks lost 18.7% of their body weight on average, compared with 15.6% on 2.4 mg. Stomach side effects were more common on the higher dose (70.8% vs 61.2%), and so were skin-sensation changes called dysaesthesia (22.9% vs 6.0%) (Wharton et al., Lancet Diabetes Endocrinol, 2025, DOI (external link)). As of September 2026 the Wegovy label allows an increase to 7.2 mg for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss. Keep in mind that STEP UP assigned doses from the start. It didn't test whether moving up breaks a plateau that has already set in.
Why plateaus happen regardless of dose
Plateaus are an expected part of losing weight by any method. Part of the reason is metabolic adaptation (adaptive thermogenesis): as you get lighter, your body burns less energy. In one long-term follow-up of people who lost large amounts of weight without medication, resting metabolic rate was still about 700 kcal a day below baseline six years later (DOI (external link)). A plateau on a GLP-1 isn't necessarily a sign your dose has "stopped working."
When a higher dose makes more sense
A dose increase is more likely to help if you're still partway through your titration schedule and haven't yet reached a dose that works for you. People respond very differently (see our guide on GLP-1 super-responders). It's also worth discussing if you and your prescriber think the appetite and fullness effects themselves have faded at your current dose, as opposed to weight loss slowing while those effects stay steady.
When a higher dose is less likely to be the answer
A common rule of thumb: if your appetite still feels well controlled but the scale isn't moving, look first at metabolic adaptation, what you're eating, and how active you are. No trial has tested that rule directly, so treat it as a question to raise with your prescriber, not a conclusion.
A higher dose is also less likely to help if you're already at or near the maximum labeled dose for your drug. Our guide on why some people stay on a lower maintenance dose explains why more isn't always available or advisable. If side effects are already hard to live with, going higher adds to them for a less certain gain. And if your goal is body recomposition more than maximum weight loss, a flat scale while your body composition keeps improving may not be a problem at all.
What else to look at during a plateau
Before assuming the dose is the issue, review your protein intake and overall nutrition (see our guide on protein, fat, and carbohydrates), your activity level including strength training, and whether a DXA scan shows the plateau is only in scale weight while fat loss continues. Then take the question to your prescriber: have the appetite effects really faded, or is this a normal pause that a higher dose is unlikely to change much?
Study findings above are attributed to their authors and were located via PubMed.
This article is for general education and is not medical advice. Decisions about your dose belong with your prescriber.